Alembic Pharmaceuticals has recently informed exchanges that the company has successfully completed the GMP audit conducted by the Brazilian Health Regulatory Agency (ANVISA) for its API-II facility in Panelav. The audit, which took place from September 16th to 20th, 2024, evaluated eight APIs.
In the exchange filing, the company shared, “We would like to inform the exchange that the Company has successfully completed the Brazilian Health Regulatory Agency (ANVISA) GMP audit at API-II Facilty at Panelav for its 8 APIs. The inspection was conducted from 16th September, 2024 to 20th September, 2024.”
In the meantime, Alembic Pharmaceuticals shares opened today at 1,100.50, reaching a high of 1,104.95 and a low of 1,082.80. Over the past 52 weeks, the stock has seen a high of 1,303.90 and a low of 746.00.
